The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway

Cancer Prevention Research

Volumn 5, Issue 6, 2012, Pages 810-821

  Cabrera, M Carla ^b   Díaz Cruz, Edgar S ^b,c   Kallakury, Bhaskar V S ^a,b   Pishvaian, Michael J ^a,b   Grubbs, Clinton J ^d   Muccio, Donald D ^d   Furth, Priscilla A ^a,b,e  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BELMONT UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DOXYCYCLINE; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOID X RECEPTOR; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL HYPERPLASIA; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIUM DYSPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIMIAN VIRUS 40; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLINS; EPITHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PIPERAZINES; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866466511     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0532-T     Document Type: Article

References (49)

1. Ewald D, Li M, Efrat S, Auer G, Wall RJ, Furth PA, et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996;273:1384-6. (Pubitemid 26296525)
2. Tilli MT, Hudgins SL, Frech MS, Halama ED, Renou J-P, Furth PA. Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression. Cancer Res 2003;63:7668-73. (Pubitemid 37466694)
3. Furth PA, Li M, Hennighausen L. Studying development of disease through temporally controlled gene expression in the salivary gland. Ann N Y Acad Sci 1998;842:181-7. (Pubitemid 28227021)
4. Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, et al. Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res 2007;174:235-43.
5. Cardiff RD, Anver MR, Boivin GP, Bosenberg MW, Maronpot RR, Molinolo AA, et al. Precancer in mice: animal models used to understand, prevent, and treat human precancers. Toxicol Pathol 2006;34:699-707. (Pubitemid 44665522)
6. Hursting SD, Nunez NP, Patel AC, Perkins SN, Lubet RA, Barrett JC. The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat Res 2005;576:80-92. (Pubitemid 40982684)
7. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
8. Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol 2001;11:15-23.
9. Yu B, Lane ME, Pestell RG, Albanese C, Wadler S. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol Cell Biol Res Commun 2000;3:352-9.
10. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23. (Pubitemid 39551659)
11. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994;91:709-13. (Pubitemid 24041471)
12. Soni S, Kaur J, Kumar A, Chakravarti N, Mathur M, Bahadur S, et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005;68:314-25. (Pubitemid 41160959)
13. Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomaki K, Heikkila P, et al. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2009;113:75-82.
14. Said TK, Moraes RC, Singh U, Kittrell FS, Medina D. Cyclin-dependent kinase (cdk) inhibitors/cdk4/cdk2 complexes in early stages of mouse mammary preneoplasia. Cell Growth Differ 2001;12:285-95. (Pubitemid 32678220)
15. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6. (Pubitemid 29242299)
16. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005;48:2388-406. (Pubitemid 40516432)
17. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
18. Michaud K, Solomon DA, Oermann E, Kim J-S, Zhong W-Z, Prados MD, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res 2010;70:3228-38.
19. Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci 2007;12:5039-51.
20. Na H-K, Surh Y-J. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol 2008;46:1271-8.
21. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
22. Tanaka T, De Luca LM. Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res 2009;69:4945-7.
23. Li Y, Shen Q, Kim H-T, Bissonnette RP, Lamph WW, Yan B, et al. The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast Cancer Res Treat 2011;128:667-77.
24. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 2006;58:1-14.
25. Mehta RG, Williamson E, Patel MK, Koeffler HP. Aligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23. (Pubitemid 30154824)
26. Pei L, Zhang Y, Zhang Y, Chu X, Zhang J, Wang R, et al. Peroxisome proliferator-activated receptor gamma promotes neuroprotection by modulating cyclin D1 expression after focal cerebral ischemia. Can J Physiol Pharmacol 2010;88:716-23.
27. Kapetanovic IM, Horn TL, Johnson WD, Cwik MJ, Detrisac CJ, McCormick DL. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention. Int J Toxicol 2010;29:157-64.
28. Jayasinghe NR, Cope GH, Jacob S. Morphometric studies on the development and sexual dimorphism of the submandibular gland of the mouse. J Anat 1990;172:115-27. (Pubitemid 20353635)
29. Díaz-Cruz ES, Furth PA. Deregulated estrogen receptor α and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res 2010;70:3965-74.
30. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protocols 2008;3:1101-8. (Pubitemid 351818697)
31. Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin T-H, Eto I, et al. 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers. Cancer Lett 2003;201:17-24. (Pubitemid 37297993)
32. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999;22:44-52.
33. Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493-504. (Pubitemid 39485668)
34. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 1995;9:2364-72.
35. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-30.
36. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
37. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
38. Massagué J. G1 cell-cycle control and cancer. Nature 2004;432:298-306. (Pubitemid 39551657)
39. Fulda S, Debatin K-M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004;23:6702-11. (Pubitemid 39280002)
40. Millar AW, Lynch KP. Rethinking clinical trials for cytostatic drugs. Nat Rev Cancer 2003;3:540-5. (Pubitemid 37328842)
41. Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A, et al. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2011 [Epub ahead of print].
42. Yang H, Landis-Piwowar K, H Chan T, P Dou Q. Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets 2011;11:296-306.
43. Bargonetti J, Reynisdóttir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 1992;6:1886-98.
44. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989;56:67-75.
45. Henning W, Rohaly G, Kolzau T, Knippschild U, Maacke H, Deppert W. MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J Virol 1997;71:7609-18. (Pubitemid 27391703)
46. Sladek TL, Laf fin J, Lehman JM, Jacobberger JW. A subset of cells expressing SV40 large T antigen contain elevated p53 levels and have an altered cell cycle phenotype. Cell Prolif 2000;33:115-25. (Pubitemid 30307239)
47. Bocchetta M, Eliasz S, De Marco MA, Rudzinski J, Zhang L, Carbone M. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth. Cancer Res 2008;68:1022-9. (Pubitemid 351272219)
48. Wu L, Goodwin EC, Naeger LK, Vigo E, Galaktionov K, Helin K, et al. E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. Mol Cell Biol 2000;20:7059-67.
49. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than Erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008;7:1251-7.